Galderma
- Business Wire
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
– Upfront and approval payments of up to $15 million – Tiered royalties ranging from mid- to high-teen percentage of…
Read More » - Business Wire
Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
Atopic dermatitis is the most common type of eczema. Moderate to severe atopic dermatitis is a chronic and incurable condition,…
Read More » - Health
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure®/ Dysport® (abobotulinumtoxinA)
Lausanne, Switzerland: Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the…
Read More » - World
Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting
Lausanne, Switzerland: Galderma today announced the presentation of data from clinical trials of its aesthetic solutions and pipeline in five…
Read More »